Autopsy report · NCT01863667
A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)
Cause of deathNo reason given
Life of this trial
- Registered 2 months before it started.
- Ran for about 9 months before it stopped.
- 65 participants enrolled.
- Results were posted on the registry 1 year 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Industry
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Omarigliptin; Glimepiride; Omarigliptin Placebo; Glimepiride Placebo
- Participants
- 65
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.